BlackRock, Inc. 13D and 13G filings for Sangamo Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-07-08 4:32 pm Sale | 2024-06-30 | 13G | Sangamo Therapeutics, Inc. SGMO | BlackRock Inc. BLK | 4,702,938 2.300% | -9,392,927 (-66.64%) | Filing |
| 2024-01-26 11:49 am Sale | 2023-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO | BlackRock Inc. BLK | 14,095,865 7.900% | -1,263,576 (-8.23%) | Filing |
| 2023-01-24 1:56 pm Purchase | 2022-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO | BlackRock Inc. BLK | 15,359,441 9.400% | 3,696,561 (+31.70%) | Filing |
| 2022-02-01 5:08 pm Purchase | 2021-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO | BlackRock Inc. BLK | 11,662,880 8.000% | 2,096,465 (+21.91%) | Filing |
| 2021-02-01 08:23 am Purchase | 2020-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO | BlackRock Inc. BLK | 9,566,415 6.800% | 32,144 (+0.34%) | Filing |